Flo Axiom, a biotechnology venture born from research at Griffith University, has successfully transitioned into a commercial venture following its participation in the 2025 LuminaX Accelerator Program, highlighting the growing opportunity to transform Australian research into real-world impact.
Originally known as BioProSep, the company now operates as Flo Axiom and is focused on improving one of the most critical stages in the manufacturing of biologic medicines.
The venture develops and manufactures bioseparation materials that enable the efficient recovery of biologics during industrial production. Based on research led by Professor Bernd Rehm and Dr Stefanie Buchholz from Griffith University’s Institute for Biomedicine and Glycomics, and supported by investment from biotech company Proto Axiom, the spin-out aims to improve how these medicines are produced at scale.
Made possible through LX Health’s partnership with Griffith University and the Gold Coast Health & Knowledge Precinct, the collaboration at Cohort Innovation Space helps researchers explore pathways to commercialisation and accelerate the transition from research to impact.
Dr Stefanie Buchholz said participating in the LuminaX Accelerator Program helped bridge the gap between research and business.
“LuminaX immersed us in the innovation ecosystem and connected us with the people, networks, and expertise needed to take our technology from being technically ready to building a company around it. The program helped accelerate our transition from researchers developing a promising technology to founders focused on creating real-world impact”
Over the course of the three-month accelerator, the founders worked alongside industry experts and mentors to better understand customer needs, market opportunities, company formation, fundraising, and commercial growth strategies.
The success of Flo Axiom is one example of the outcomes LX Health and its partners are working to create through the LuminaX Accelerator Program.
LX Health Director Dren Xerxa said stories like Flo Axiom’s can help inspire more researchers to pursue entrepreneurship.
“It has been inspiring to see the growth that Stefanie and Bernd have made in the span of just three months, and it goes to show the drive that these scientists, now also founders, have to create real change.”
“This will not only benefit more researchers looking to commercialise their innovations, but also have a positive impact on Australia’s capability. I’m excited to see more stories coming through our upcoming cohorts.”
As Australia’s innovation ecosystem continues to mature, Cohort Innovation Space is proud to support LX Health and Flo Axiom’s transition from a university research project to an operating biotechnology company.
This success demonstrates the value of supporting researchers with the commercial skills, connections, and confidence needed to bring innovation beyond the lab and into the market.
END